Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study
Session type: Poster / e-Poster / Silent Theatre session
1Royal Marsden Hospital, Sutton, UK, 2M.D. Anderson, Houston, Texas, USA, 3Duke University Medical Centre, Durham, USA, 4GlaxoSmithKline, Research Triangle Park, USA
Pazopanib (paz) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-kit; lapatinib (lap) is an oral tyrosine kinase inhibitor of EGFR and HER2. The combination may provide synergistic activity in malignant glioma. The efficacy of daily paz/lap (400mg/1000mg) in relapsed grade 4 glioma was previously reported. This study determined the optimally tolerated regimen (OTR) of paz/lap when given with enzyme-inducing anticonvulsants (EIACs).
Patients (pts) with Grade 3 or 4 glioma were treated with escalating doses of paz/lap in a 3+3 design.